uMotif, Xperiome: rare-disease study collaboration
By Jenni Spinner
- Last updated on
Clinical solutions firm uMotif has announced plans to work with rare-disease tech specialist Xperiome to explore novel approaches to patient recruitment. The approach reportedly will use digital patient community technology and an innovative patient engagement platform.
uMotif CEO Bruce Hellman said, “Having access to reliable patient data during clinical trials is crucial and it requires effective patient recruitment and engagement strategies. Xperiome and uMotif share a commitment to eliminating the friction in clinical trial enrollment, reducing the burden on both sites and participating patients; our partnership is designed with patients in mind, to help sponsors and research professionals capture the best quality data in a way that suits study participants. It’s a win-win for all stakeholders and has the potential to aid in accelerating the delivery of vital therapies to patients who need them.”